SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

NCT05900882 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Selinexor
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

The First Affiliated Hospital with Nanjing Medical University